QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

VENLO, the Netherlands--(BUSINESS WIRE)--January 15, 2025-- 

QIAGEN N.V. $(QGEN)$ (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024.

Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time.

Three options for joining the conference call

Register for call back connection - Click here: Connect me

Service is available 15 minutes before the call starts

Dial-in by phone

U.S.: +1 646 828 8193

UK: +44 (0)330 165 4027

GER: +49 (0)69 6610 2480

Conference ID: 9237018

To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.

Access the audio webcast - Click here: Access Webcast

A conference call replay will be available by using the following link:

https://event.webcasts.com/starthere.jsp?ei=1684130&tp_key=c56f1d6ba2

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

Source: QIAGEN N.V.

Category: Financial

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115503089/en/

 
    CONTACT:    John Gilardi 

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711

+49 152 018 11711

+1 240 686 2222

Email: ir@qiagen.com

Domenica Martorana

Associate Director Investor Relations

+49 2103 29 11244

+49 152 018 11244

Email: ir@qiagen.com

(END) Dow Jones Newswires

January 15, 2025 08:18 ET (13:18 GMT)